Methods and compositions for treating flaviviruses and pestiviruses
View Patent ↗A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
1. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising administering to a host infected with a flavivirus or a pestivirus an anti-virally effective amount of a compound of Formula XI:
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine or pyrimidine base;
R 1 and R 2 are independently H; phosphate; mono phosphate; diphosphate; triphosphate; a stabilized phosphate prodrug; acyl; lower acyl; alkyl; lower alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate or phosphonate; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R 1 or R 2 is independently H or phosphate;
R 6 is alkyl;
R 7 is azido, cyano, alkynyl, or NH 2 ; and
X is O or S.
2. The method of claim 1 , wherein R 1 and R 2 are independently H; phosphate; monophosphate; diphosphate; triphosphate; or a stabilized phosphate prodrug.
3. The method of claim 1 , wherein R 1 and R 2 are each hydrogen.
4. The method of claim 1 , wherein X is O.
5. The method of claim 1 , wherein R 6 is methyl.
6. The method of claim 1 , wherein Base is a purine or pyrimidine base selected from adenine, N6-alkyl purine, N6-acyl purine, N6-benzylpurine, N6-halopurine, N6-vinylpurine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkyl purine, N2-alkyl-6-thiopurine, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, 6-azacytosine, 2- and/or 4-mercaptopyrimidine, uracil, 5-halouracil, 5-fluorouracil, C5-alkylpyrimidine, C5-benzyl pyrimidine, C5-halopyrimidine, C5-vinyl pyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, C5-aminopyrimidine, N2-alkyl purine, N2-alkyl-6-thiopurine, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, guanine, hypoxanthine, 2,6-diaminopurine, or 6-chloropurine.
7. The method of claim 1 , wherein Base is a purine or pyrimidine base selected from adenine, thymine, cytosine, uracil or guanine.
8. The method of claim 1 , wherein Base is cytosine or uracil.
9. The method of claim 1 , wherein the flavivirus or pestivirus is selected from dengue hemorrhagic fever virus, yellow fever virus, shock syndrome or Japanese encephalitis virus.
10. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising contacting a cell infected with a flavivirus or a pestivirus with an anti-virally effective amount of a compound of Formula XI:
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine or pyrimidine base;
R 1 and R 2 are independently H; phosphate; monophosphate; diphosphate; triphosphate; a stabilized phosphate prodrug; acyl; lower acyl; alkyl; lower alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate or phosphonate; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R 1 or R 2 is independently H or phosphate;
R 6 is alkyl;
R 7 is azido, cyano, alkynyl, or NH 2 ; and
X is O or S.
11. The method of claim 10 , wherein R 1 and R 2 are independently H; phosphate; monophosphate; diphosphate; triphosphate; or a stabilized phosphate prodrug.
12. The method of claim 10 , wherein R 1 and R 2 are each hydrogen.
13. The method of claim 10 , wherein X is O.
14. The method of claim 10 , wherein R 6 is methyl.
15. The method of claim 10 , wherein Base is a purine or pyrimidine base selected from adenine, N6-alkyl purine, N6-acyl purine, N6-benzyl purine, N6-halopurine, N6-vinyl purine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkyl purine, N2-alkyl-6-thiopurine, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, 6-azacytosine, 2- and/or 4-mercaptopyrimidine, uracil, 5-halouracil, 5-fluorouracil, C5-alkylpyrimidine, C5-benzyl pyrimidine, C5-halopyrimidine, C5-vinyl pyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, C5-aminopyrimidine, N2-alkylpurine, N2-alkyl-6-thiopurine, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, guanine, hypoxanthine, 2,6-diaminopurine, or 6-chloropurine.
16. The method of claim 10 , wherein Base is a purine or pyrimidine base selected from adenine, thymine, cytosine, uracil or guanine.
17. The method of claim 10 , wherein Base is cytosine or uracil.
18. The method of claim 10 , wherein the flavivirus or pestivirus is selected from dengue hemorrhagic fever virus, yellow fever virus, shock syndrome or Japanese encephalitis virus.
19. A method for the treatment of a flavivirus or pestivirus infection in a host, comprising contacting a flavivirus or pestivirus polymerase with an anti-virally effective amount of a compound of Formula XI:
or a phosphate thereof, or a pharmaceutically acceptable salt or ester thereof, wherein:
Base is a purine or pyrimidine base;
R 1 and R 2 are independently H; phosphate; monophosphate; diphosphate; triphosphate; a stabilized phosphate prodrug; acyl; lower acyl; alkyl; lower alkyl; sulfonate ester; alkyl sulfonyl; arylalkyl sulfonyl; methanesulfonyl; benzyl, wherein the phenyl group is optionally substituted with one or more substituents selected from the group consisting of hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate or phosphonate; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; a cholesterol; or other pharmaceutically acceptable leaving group which when administered in vivo provides a compound wherein R 1 or R 2 is independently H or phosphate;
R 6 is alkyl;
R 7 is azido, cyano, alkynyl, or NH 2 ; and
X is O or S.
20. The method of claim 19 , wherein R 1 and R 2 are independently H; phosphate; monophosphate; diphosphate; triphosphate; or a stabilized phosphate prodrug.
21. The method of claim 19 , wherein R 1 is triphosphate and R 2 is hydrogen.
22. The method of claim 19 , wherein X is O.
23. The method of claim 19 , wherein R 6 is methyl.
24. The method of claim 19 , wherein Base is a purine or pyrimidine base selected from adenine, N6-alkyl purine, N6-acyl purine, N6-benzyl purine, N6-halopurine, N6-vinyl purine, N6-acetylenic purine, N6-acyl purine, N6-hydroxyalkyl purine, N6-thioalkyl purine, N2-alkyl purine, N2-alkyl-6-thiopurine, thymine, cytosine, 5-fluorocytosine, 5-methylcytosine, 6-azapyrimidine, 6-azacytosine, 2- and/or 4-mercaptopyrimidine, uracil 5-halouracil, 5-fluorouracil C5-alkyl pyrimidine, C5-benzylpyrimidine, C5-halopyrimidine, C5-vinyl pyrimidine, C5-acetylenic pyrimidine, C5-acyl pyrimidine, C5-hydroxyalkyl purine, C5-amidopyrimidine, C5-cyanopyrimidine, C5-nitropyrimidine, C5-aminopyrimidine, N2-alkylpurine, N2-alkyl-6-thiopurine, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, guanine, hypoxanthine, 2,6-diaminopurine, or 6-chloropurine.
25. The method of claim 19 , wherein Base is a purine or pyrimidine base selected from adenine, thymine, cytosine, uracil or guanine.
26. The method of claim 19 , wherein Base is cytosine or uracil.
27. The method of claim 19 , wherein the flavivirus or pestivirus is selected from dengue hemorrhagic fever virus, yellow fever virus, shock syndrome or Japanese encephalitis virus.